The latest price target for Elevation Oncology (NASDAQ:ELEV) was reported by HC Wainwright & Co. on August 7, 2024. The analyst firm set a price target for $6.00 expecting ELEV to rise to within 12 months (a possible 883.61% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Elevation Oncology (NASDAQ:ELEV) was provided by HC Wainwright & Co., and Elevation Oncology reiterated their buy rating.

The last upgrade for Elevation Oncology Inc happened on May 30, 2023 when SVB Securities raised their price target to $8. SVB Securities previously had a market perform for Elevation Oncology Inc.

The last downgrade for Elevation Oncology Inc happened on November 10, 2022 when JP Morgan changed their price target from N/A to N/A for Elevation Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevation Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevation Oncology was filed on August 7, 2024 so you should expect the next rating to be made available sometime around August 7, 2025.

While ratings are subjective and will change, the latest Elevation Oncology (ELEV) rating was a reiterated with a price target of $6.00 to $6.00. The current price Elevation Oncology (ELEV) is trading at is $0.61, which is out of the analyst’s predicted range.